Macuject Secures $129M to Revolutionize AI-Driven Care in the Fight Against Preventable Blindness

Macuject is thrilled to announce a landmark achievement with the successful raise of US$129,000,000 in our latest funding round—a pivotal milestone in our mission to end preventable blindness worldwide.

As a clinician-driven digital health company, we remain steadfast in our commitment to combat conditions that rob millions of their sight, beginning with age-related macular degeneration (AMD), and expanding our impact to address diabetic retinopathy, cataract, and glaucoma.

Our cutting-edge clinical decision support software harnesses the power of artificial intelligence, enabling healthcare professionals to make precise, timely diagnoses and craft individualized treatment plans that optimize patient outcomes.

This robust financing will be strategically allocated to accelerating research and development initiatives, refining our SaaS solutions, and further integrating our platform seamlessly within existing healthcare infrastructures across the globe.

Under the visionary leadership of our founder-CEO, Dr.

Devinder Chauhan—a renowned Melbourne retinal specialist whose contributions account for 8% of AMD treatments in his state—Macuject is uniquely positioned to transform the landscape of ocular diagnostics and care.

Our talented, multidisciplinary team continues to work collaboratively, combining clinical excellence with commercial acumen and technical innovation, ensuring that our products remain both clinically relevant and widely adopted.

With this injection of capital, we are poised to enhance our software’s capabilities, expand our market presence, and ultimately bring personalized care to the forefront of digital health, thus reducing the socioeconomic burden of blindness on communities and safeguarding the quality of life for tens of millions around the globe.